Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Aspirin for Endometrial Cancer Prevention
NCT07281547Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Feb 2027
- Primary completion
- Jun 2028
- Countries
- 1
- Sponsor
- Mayo Clinic
- Modality
- Orthosteric Ligands
- Drugs
- aspirin
- Conditions
- endometrial carcinoma
01
Overview
Phase 4, randomised, open-label trial in endometrial carcinoma comparing Arm I (low dose aspirin) with Arm II (observation) (2 arms). Primary endpoint: Change in prostaglandin E2 at 6 weeks. Planned start Feb 2027; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Arm I (low dose aspirin)
Low dose aspirin PO QD for up to 42 days
Arm II (observation)
Observation for up to 42 days
03
Who it enrols
Postmenopausal women with a uterus, non-atrophic endometrial changes, and pain warranting endometrial sampling, without a history of gynecologic cancers or precancers.
04
Endpoints
Primary
Change in prostaglandin E2
Secondary
Facilitators and Barriers to Participating in a Clinical Trial After Consenting to Clinical Trial
Beyond the preview
Go deeper on NCT07281547.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281547.